mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2017-8-4-6-13mvjr-521Research ArticleОБЗОРЫREVIEWМелкоклеточный рак лёгкогоSmall-cell lung cancerБахмутскийН. Г.BakhmutskyNicolay G.

д.м.н., профессор, кафедра онкологии с курсом торакальной хирургии

Краснодар, Россия.

Krasnodar, Russia

bachnik@mail.ruПорхановВ. А.PorkhanovVladimir A.

д.м.н., профессор, академик РАН; заведующий кафедрой, кафедра онкологии с курсом торакальной хирургии

Краснодар, Россия

Krasnodar, Russia

БодняВ. Н.BodnyaVadim N.

д.м.н., кафедра онкологии с курсом торакальной хирургии, доцент кафедры

Краснодар, Россия

Krasnodar, Russia

ШиряевР. П.SchiryayevRostislav P.

ассистент, кафедра онкологии с курсом торакальной хирургии

Краснодар, Россия

Krasnodar, Russia

Кубанский государственный медицинский университетРоссияKuban State Medical UniversityRussian Federation20173012201784613Copyright © Бахмутский Н.Г., Порханов В.А., Бодня В.Н., Ширяев Р.П., 20172017Бахмутский Н.Г., Порханов В.А., Бодня В.Н., Ширяев Р.П.Bakhmutsky N.G., Porkhanov V.A., Bodnya V.N., Schiryayev R.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/521

Рак лёгкого – одно из самых распространённых злокачественных новообразований в мире. В настоящее время отечественных публикаций, рассматривающих вопросы классификации, клиники, диагностики, лечения мелкоклеточного рака, одной из форм рака лёгкого, крайне мало. Представленный обзор литературы посвящён мелкоклеточному раку лёгкого, опухоли, имеющей агрессивное клиническое течение и неблагоприятный прогноз. В обзоре рассмотрены вопросы эпидемиологии, клинической и морфологической классификации мелкоклеточного рака лёгкого, рекомендуется наиболее приемлемая клиническая классификация, которая подразделяет опухоль на две формы (локальную, или ограниченную, и распространённую). В работе уделяется внимание стандартным вариантам лечения локальной и распространённой форм мелкоклеточного рака лёгкого. В лечении локальной формы подтверждена основная роль химиотерапии с лучевой терапией, комбинированной химиотерапии, хирургического лечения с последующей химиотерапией или химиолучевым лечением. Для лечения распространённой формы указаны такие варианты лечения, как комбинированная химиотерапия и лучевая терапия. Отмечены успехи и недостатки в лечении этой опухоли полихимиотерапией, лучевой терапией и комбинированной терапией, а также указывается на разработку новых схем и комбинаций лечения с большей эффективностью и меньшей токсичностью для больных. Отдельно рассмотрены вопросы терапии рецидивов мелкоклеточного рака лёгкого, отмечена основная роль в лечении химиотерапии и паллиативного лечения. Показано значение облучения головного мозга в плане снижения рецидивирования и увеличения продолжительности жизни при этой патологии

Lung cancer – one of the most common malignancies in the world. Currently, domestic publications addressing issues of classifi cation, clinic, diagnosis, treatment, a form of lung cancer - non-small cell cancer, is extremely small. Th erefore, our work makes up to some extent this gap. Th is review of literature devoted to small-cell lung cancer, the tumor has an aggressive clinical course and poor prognosis. Th e review considers the epidemiology, clinical and morphological classifi cation of small cell lung cancer; it is recommended the most appropriate clinical classifi cation, which classifi es tumors into two forms — limited or local and extensive. Th e paper focuses on the standard options of treatment of limited form and extensive form of non-small cell lung cancer. In the treatment of limited form confi rmed the primary role of chemotherapy with radiation therapy, combination chemotherapy, surgery followed by chemotherapy or chemoradiotherapy. For the treatment of extensive form shown in the use of such treatment options as combination chemotherapy and radiotherapy. It noted the successes and shortcomings in the treatment of this tumor chemotherapy, radiation therapy, and combination therapy, and also points to the development of new schemes and treatment combinations with greater effi ciency and less toxicity for patients. Separately, the issues of treatment of small cell lung cancer recurrence and noted the major role in the treatment of chemotherapy and palliative care. Th e importance of brain irradiation in reducing recurrence and increase survival in this pathology.

обзоррак лёгкогомелкоклеточный рак лёгкогохимиотерапиялучевая терапияlung cancersmall-cell lung cancerchemotherapyradiotherapyРабота была поддержана грантом РФФИ (договор №16-04-01146).ReferencesЗлокачественные новообразования в России в 2014 году (Заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. – М., 2016.Zlokachestvennye novoobrazovanija v Rossii v 2014 godu (Zabolevaemost’ i smertnost’). Moscow, 2016. (In Russ.)Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics // CA Cancer J. Clin. – 2011. – Vol. 61 (2). – P. 69-90. doi: 10.3322/caac.20107Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107Kelley M.J., Bogart J.A., Hodgson L.D., Ansari R.H., Atkins J.N., Pang H. et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206 // J.Th orac.Oncol. – 2013. – Vol. 8 (1). – P.102-8. doi: 10.1097/JTO.0b013e31827628e1Kelley MJ, Bogart JA, Hodgson LD, Ansari RH, Atkins JN, Pang H, et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. J.Th orac.Oncol. 2013;8(1):102-8. doi: 10.1097/JTO.0b013e31827628e1Bradley J.D., Dehdashti F., Mintun M.A., Govindan R., Trinkaus K., Siegel B.A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study // J. Clin. Oncol. – 2004. – V. 22 (16). – P. - 3248-54. DOI: 10.1200/JCO.2004.11.089Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J. Clin. Oncol. 2004;22(16):3248-54. DOI: 10.1200/JCO.2004.11.089Salama J.K., Hodgson L., Pang H., Urbanic J.J., Blackstock A.W., Schild S.E., et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy CALGB 30904 // J.Th orac.Oncol. – 2013. – Vol. 8 (8). – P. 1043-9. doi: 10.1097/JTO.0b013e318293d8a4Salama JK, Hodgson L, Pang H, Urbanic JJ, Blackstock AW, Schild SE, et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy CALGB 30904. J.Th orac.Oncol. 2013;8(8):1043-9. doi: 10.1097/JTO.0b013e318293d8a4Lung. In: Edge S.B., Byrd D.R., Compton C.C. et al., eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer. – 2010. – P. 253-70.Lung. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.Aynaci O., Canyilmaz E., Serdar L. Kandaz M., Bahat Z.M., Yoney A. Survival and prognostic factors in limited stage small cell lung cancer: A retrospective study from northeast Turkey // Cancer Res. – 2016. – V. 12(1). – P. 238-243. doi: 10.4103/0973-1482.151446Aynaci O, Canyilmaz E, Serdar L, Kandaz M, Bahat ZM, Yoney A. Survival and prognostic factors in limited stage small cell lung cancer: A retrospective study from northeast Turkey. Cancer Res. 2016;12(1):238-243. doi: 10.4103/0973-1482.151446Sekine I., Yamamoto N., Kunitoh H., Ohe Y., Tamura T., Kodama T., et al. Treatment of small cell lang cancer in the elderly based on a critical literature review of clinical trials // Cancer Treat. Rev. – 2004. - V. 30(4). – P. 359-68. doi: 10.1016/j.ctrv.2003.12.006Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, et al. Treatment of small cell lang cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat. Rev. 2004;30(4):359-68. doi: 10.1016/j.ctrv.2003.12.006Videtic G.M., Stitt L.W., Dar A.R., Kocha W.I., Tomiak A.T., Truong P.T. et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival // J. Clin. Oncol. – 2003. – V. 21 (8). – P. 1544-9. doi: 10.1200/JCO.2003.10.089Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J. Clin. Oncol. 2003;21(8):1544-9. doi: 10.1200/JCO.2003.10.089Chandra V., Allen M.S., Nichols F.C., Deschamps C., Cassivi S.D., Pairolero P.C. Th e role of pulmonary resection in small cell lung cancer // Mayo Clin. Proc. – 2006. – V. 81 (5). – P. 619-24. doi: 10.4065/81.5.619Chandra V, Allen MS, Nichols FC, Deschamps C, Cassivi SD, Pairolero PC. Th e role of pulmonary resection in small cell lung cancer. Mayo Clin. Proc. 2006;81(5):619-24. doi: 10.4065/81.5.619Takada M., Fukuoka M., Kawahara M. et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104 // J. Clin. Oncol. – 2002. – V. 20 (14). – P. 3054-60.Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J. Clin. Oncol. 2002;20(14):3054-60. DOI: 10.1200/JCO.2002.12.071Бычков М.Б. Мелкоклеточный рак лёгкого // Практическая онкология. – 2005. – Том 6, №4. – С. 213-219.Bychkov MB, Dgebuadze EN, Bol’shakova SA. Melkokletochnyi rak legkogoю Prakticheskaya onkologiya. 2005;6(4):213-219. (In Russ.)Slotman B. J., Faivre-Finn C., Kramer G. et al. Prophylactic cranial irradiation in extensive small-cell lung cancer // N. Engl. J. Med. – 2007. – V. 357 (7). – P. 664-72.Slotman BJ, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N. Engl. J. Med. 2007;357(7):664-72. DOI: 10.1056/NEJMoa071780Slotman B. J., van Tinteren H., Praag J.O. et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial // Lancet. – 2015. – V. 385 (9962). – P. 36-42.Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36-42. doi: 10.1016/S0140-6736(14)61085-0Amarasena I.U., Walters J.A., Wood-Baker R. et al.: Platinum versus non-platinum chemotherapy regimens for small cell lung cancer // Cochrane Database Syst. Rev. (4): CD006849, 2008.Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst. Rev. (4):CD006849, 2008. doi: 10.1002/14651858.CD006849.pub3Багрова С.Г., Бычков М.Б., Горбунова В.А. и др. Сравнительная оценка различных платиносодержащих режимов химиотерапии в лечении распространённого мелкоклеточного рака лёгкого (опыт отделения химиотерапии РОНЦ им. Н.Н. Блохина РАМН) // Рос. онкол. журнал. – 2013. - №2. – С. 4-10.Bagrova SG, Bychkov MB, Gorbunova VA, Kuzminov AE, Naskhletashvili DR. Comparative evaluation of diff erent regimen of platinum-based chemotherapy in treatment of advanced small cell lung cancer (experience of chemotherapy department N.N.Blokhin Russian Cancer Research Center RAMS). Russian Journal of Oncology. 2013;(2):4-10. (In Russ.)Spiro S.G., James L.E., Rudd R.M. et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis // J.Clin.Oncol. – 2006. – Vol. 24 (24). – P. 3823-30.Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J.Clin.Oncol. 2006;24(24):3823-30. DOI: 10.1200/JCO.2005.05.3181De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J. et al. Systematic review and meta-analysis of randomized, controlled trials of the timing of chest radiotherapy in patients with limited stage, small-lung cancer // Ann. Oncol. – 2006. – V. 17 (4). – P. 543-52.De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and metaanalysis of randomized, controlled trials of the timing of chest radiotherapy in patients with limited stage, smalllung cancer. Ann. Oncol. 2006;17(4):543-52. DOI: 10.1093/annonc/mdj094Fried D.B., Morris D.E., Poole C. et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer // J.Clin.Oncol. – 2004. – Vol. 22 (23). – P. 4837-45.Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J.Clin.Oncol. 2004;22(23):4837-45. DOI: 10.1200/JCO.2004.01.178Huncharek M., McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer // Oncologist. – 2004. – Vol. 9 (6). – P. 665-72.Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist. 2004;9(6):665-72. DOI: 10.1634/theoncologist.9-6-665Pijls-Johannesma M., De Ruysscher D., Lambin P. et al. Early versus late chest radiotherapy for limited stage small cell lung cancer // Cochrane Database Syst. Rev. - (1).- CD004700 – 2005.Pijls-Johannesma M, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst. Rev. 2005;(1):CD004700. DOI: 10.1002/14651858.CD004700.pub2De Ruysscher D., Pijls-Johannesma M., Bentzen S.M. et al. Time between the fi rst day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer // J.Clin.Oncol. – 2006. – P. 1057-63.De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, et al. Time between the fi rst day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J.Clin.Oncol. 2006;24(7):1057-63. DOI: 10.1200/JCO.2005.02.9793Гулидов И.А., Золотков А.Г., Мардынский Ю.С. и др. Сравнение традиционной лучевой терапии с методикой ускоренного гиперфракционирования в химиолучевом лечении локализованного мелкоклеточного рака лёгкого // Сибирский онкологический журнал. – 2013. - №1 (55). – С. 12-15.Gulidov IA, Zolotkov AG, Mardynsky YS, Ivanova IN, Kursova LV, et al. Comparison of conventional radiatiotherapy and accelerated hyperfractionated radiatiotherapy in chemoradiation treatment for small cell lung cancer. Siberian journal of oncology. 2013;(1):12-15. (In Russ.)Bogart J.A., Herndon J.T., Lyss A.P. et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-disease small-cell lung cancer; analysis of Cancer and Leukemia Group B study 39808 // Int.J.Radiat.Oncol.Biol. Phys. – 2004. – Vol. 59 (2). – P. 460-8.Bogart JA, Herndon JT, Lyss AP, Watson D, Miller AA, Lee ME, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-disease small-cell lung cancer; analysis of Cancer and Leukemia Group B study 39808. Int.J.Radiat.Oncol.Biol.Phys. 2004;59(2):460-8. DOI: 10.1016/j.ijrobp.2003.10.021Miller A.A., Wang X.F., Bogart J.A. et al. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 // J.Th orac.Oncol. – 2007. – Vol. 2 (7). – P. 645-51.Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, et al. Phase II trial of paclitaxel-topotecanetoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J.Th orac.Oncol. 2007;2(7):645-51. DOI: 10.1097/JTO.0b013e318074bbf5Колбанов К.И., Трахтенберг А.Х., Пикин О.В. Возможности хирургии при резектабельном мелкоклеточном раке лёгкого // Онкология. Журнал им. П.А. Герцена. – 2017. – Т.6, №3. – С. 67-75.Kolbanov KI, Trakhtenberg AKh, Pikin OV. Vozmozhnosti khirurgii pri rezektabel’nom melkokletochnom rake legkogo. Onkologiya. Zhurnal im. P.A. Gertsena. 2017;6(3):67-75. (in Russ.)Okamoto H., Watanabe K., Kunikane H. et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 // Br. J. Cancer. – 2007. – Vol. 97 (2). – P. 162-9.Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease smallcell lung cancer: JCOG 9702. Br. J. Cancer. 2007;97(2):162-9. DOI: 10.1038/sj.bjc.6603810Hanna N., Bunn P.A., Langer C. et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer // J. Clin. Oncol. – 2006. – Vol. 24 (13). - P. 2038-43.Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie TJr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 2006;24(13):2038-43. DOI: 10.1200/JCO.2005.04.8595Lara P.N., Natale R., Crowley J. et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 // J. Clin. Oncol. – 2009. – Vol. 27 (15). – P. 2530-5.Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 2009;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061Schmittel A., Sebastian M., Fischer von Weikersthal L. et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as fi rst-line therapy for extensive-disease small-cell lung cancer // Ann. Oncol. – 2011. – Vol. 22 (8). – P. 1798-804.Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as fi rst-line therapy for extensivedisease small-cell lung cancer. Ann. Oncol. 2011;22(8):1798-804. doi: 10.1093/annonc/mdq652Zatloucal P., Cardenal F., Szczesna A. et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease // Ann. Oncol. – 2010. – Vol. 21 (9). – P. 1810-6.Zatloucal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann. Oncol. 2010;21(9):1810-6. doi: 10.1093/annonc/mdq036Jiang J., Liang X., Zhou X. et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer // J. Th orac. Oncol. – 2010. – Vol. 5 (6). – P. 867-73.Jiang J, Liang X, Zhou X, Huang L, Huang R, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J. Th orac. Oncol. 2010;5(6):867-73.Guo S., Liang Y., Zhou Q. Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/ cisplatin as fi rst-line chemotherapy // J. Th orac. Oncol. – 2011. – Vol. 6 (2). - P. 406-8.Guo S, Liang Y, Zhou Q. Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as fi rst-line chemotherapy. J. Th orac. Oncol. 2011;6(2):406-8. doi: 10.1097/JTO.0b013e3182061d8cEckardt J.R., von Pawel J., Pujol J.L. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer // J. Clin. Oncol. – 2007. – Vol. 25 (15). – P. 2086-92.Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 2007;25(15):2086-92. DOI: 10.1200/JCO.2006.08.3998Niell H.B., Herndon J.E., Miller A.A. et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732 // J. Clin. Oncol. – 2005. – Vol. 23 (16). – P. 3752-9.Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J. Clin. Oncol. 2005;23(16):3752-9. DOI: 10.1200/JCO.2005.09.071Th atcher N., Girling D.J., Hopwood P. et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party // J. Clin. Oncol. – 2000. – Vol. 18 (2). – P. 395-404.Th atcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colonystimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J. Clin. Oncol. 2000;18(2):395-404. DOI: 10.1200/JCO.2000.18.2.395Lorigan P., Woll P.J., O’Brien M.E. et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer // J. Natl. Cancer Inst. – 2005. – Vol. 97 (9). – P. 666-74.Lorigan P, Woll PJ, O’Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J. Natl. Cancer Inst. 2005;97(9):666-74. DOI: 10.1093/jnci/dji114Buchholz E., Manegold C., Pilz L. et al. Standard versus dose-intensifi ed chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis // J. Th orac. Oncol. – 2007. – Vol. 2 (1). – P. 51-8.Buchholz E, Manegold C, Pilz L, Th atcher N, Drings P. Standard versus dose-intensifi ed chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J. Th orac. Oncol. 2007;2(1):51-8. DOI: 10.1097/JTO.0b013e31802baf9dShivnani A.T. Prophylactic cranial irradiation in small-cell lung cancer // N. Engl. J. Med. – 2007. – Vol. 357 (19). – P. 30-34. Shivnani AT: Prophylactic cranial irradiation in smallcell lung cancer. N Engl J Med 357 (19): 1977; author reply 1978, 2007.Shivnani AT. Prophylactic cranial irradiation in smallcell lung cancer. N. Engl. J. Med. 2007;357(19):30-34. DOI: 10.1056/NEJMc072691Davies A.M., Ewans W.K., Mackay J.A. et al. Treatment of recurrent small cell lung cancer // Hematol. Oncol. Clin. Noth. Am. – 2004. – Vol. 18 (2). – P. 387-416.Davies AM, Ewans WK, Mackay JA, Shepherd FA. Treatment of recurrent small cell lung cancer. Hematol. Oncol. Clin. Noth. Am. 2004;18(2):387-416. DOI: 10.1016/j.hoc.2003.12.010van der Lee I., Smit E.F., van Putten J.W. et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer // Ann. Oncol. – 2001. - Vol. 12 (4). – P. 557-61.van der Lee I, Smit EF, van Putten JW, Groen HJ, Schlösser NJ, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann. Oncol. 2001;12(4):557-61.Eckardt J.R., von Pawel J., Papai Z. et al. Open-label, multicenter, randomized phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-native patients with extensive-disease small-cell lung cancer // J. Clin. Oncol. – 2006. – Vol. 24 (13). – P. 2044-51.Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, et al. Open-label, multicenter, randomized phase III study comparing oral topotecan/cisplatin versus etoposide/ cisplatin as treatment for chemotherapy-native patients with extensive-disease small-cell lung cancer. J. Clin. Oncol. 2006;24(13):2044-51. DOI: 10.1200/JCO.2005.03.3332Rocha-Lima C.M., Herndon J.E., Lee M.E. et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902 // Ann. Oncol. – 2007. -Vol. 18 (2). – P. 331-7.Rocha-Lima CM, Herndon JE, Lee ME, Atkins JN, Mauer A, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann. Oncol. 2007;18(2):331-7. DOI: 10.1093/annonc/mdl375

The authors declare that there are no conflicts of interest present.